Evaluation of the effects of Ellagic acid on patients with myocardial infarctio
Phase 2
Recruiting
- Conditions
- Myocardial infarction.ST elevation (STEMI) and non-ST elevation (NSTEMI) myocardial infarction
- Registration Number
- IRCT20220516054874N8
- Lead Sponsor
- Mashhad University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Patients with myocardial infarction according to the American College of Heart criteria
Consent to admission to the study
Age more than 18 years old
No kidney failure under hemodialysis
No kidney failure and GFR<30
No severe liver failure with liver enzymes three times more than normal
No treatment with diltiazem or verapamil
No previous treatment with Ellagic acid
Exclusion Criteria
Lack of consent to continue the study
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Changes in hs-CRP serum level. Timepoint: At the beginning of the study and after 4 weeks of treatment. Method of measurement: Laboratory kit.
- Secondary Outcome Measures
Name Time Method Changes in CBC diff. Timepoint: At the beginning of the study and after 4 weeks of treatment. Method of measurement: Laboratory kit.;Changes in lipid profile. Timepoint: At the beginning of the study and after 4 weeks of treatment. Method of measurement: Laboratory kit.;Changes in Interleukin-6 level. Timepoint: At the beginning of the study and after 4 weeks of treatment. Method of measurement: Laboratory kit.